Lastly, in view of our findings on the tumour suppressor role of CaSR in CML (Fig. 3b, d), we tested the effect of the CaSR agonist and calcimimetic cinacalcet40 on CML development (Supplementary Fig. 21a). Here, CASR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.